Globus Medical (GMED) Tops Q4 EPS by 17c, provides guidance

Globus Medical (NYSE: GMED) reported Q4 EPS of $1.28, $0.17 better than the analyst estimate of $1.11. Revenue for the quarter came in at $826.4 million versus the consensus estimate of $792.72 million.

GUIDANCE:

Globus Medical sees FY2026 EPS of $4.40-$4.50, versus the consensus of $4.24. Globus Medical sees FY2026 revenue of $3.18-3.22 billion, versus the consensus of $3.163 billion.

For earnings history and earnings-related data on Globus Medical (GMED) click here.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance
• RH (RH) Tops Q1 EPS by 12c